Using vaccine-induced immunity from stem cell donors to protect transplant recipients from virus reactivation
Official title: Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation
Funded at Beckman Research Institute/city of Hope · NIH-11094840 · Data updated 2026-11-12
This study is looking at whether giving stem cell transplant patients cells from donors who have been vaccinated against cytomegalovirus (CMV) can help keep them safe from getting sick from this virus after their transplant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | May 2, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $648,910 |
| NIH project number | 5R01CA266783-03 |
| Project ID | NIH-11094840 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are high-risk transplant recipients, particularly those receiving stem cells from vaccinated donors.
✕Less likely to help
Patients who are not undergoing stem cell transplantation or those who do not have a risk of CMV reactivation may not benefit from this research.
What this research studies
This research investigates how transferring immunity from vaccinated stem cell donors can help protect high-risk transplant recipients from cytomegalovirus (CMV) reactivation. The approach involves vaccinating the stem cell donors with a modified vaccine that targets CMV, which has shown promising results in preliminary studies. By enhancing the immune response in donors, the goal is to improve outcomes for transplant recipients who are at risk of developing CMV-related complications. Patients participating in this research may receive stem cells from vaccinated donors, potentially leading to better protection against CMV.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of CMV reactivation in transplant recipients, improving their overall health outcomes.
How similar studies have gone: Previous studies have shown success with similar approaches, particularly in enhancing immunity through vaccination in transplant settings.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Diamond, Don J — Beckman Research Institute/city of Hope
- Study coordinator: Diamond, Don J
Related research
Other NIH-funded projects on the same topics.
-
Vaccine-based antiviral protection for high-risk transplant recipients against CMV relapse
A patient-focused approach uses a CMV vaccine given to stem cell donors to help protect transplant recipients from cytomegalovirus reactivation.
-
COVID-19 vaccine responses in kidney transplant patients taking mycophenolate
This project looks at how the anti-rejection drug mycophenolate affects COVID-19 vaccine protection in people with kidney transplants.
-
Understanding how kidney transplant patients respond to COVID-19 vaccination while on specific immunosuppressive therapy
This study is looking at how kidney transplant patients taking a medication called mycophenolate mofetil (MMF) respond to COVID-19 vaccines, and whether stopping this medication before getting vaccinated could help them build a stronger immune response and better protect them against the virus.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.